SCHEMBL67470

SCHEMBL67470

C[C](C)C1CCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770046 0.83 PIP5K1C (0.30)
SCHEMBL8029968 0.82
SCHEMBL19573892 0.79
SCHEMBL22448448 0.79
SCHEMBL19573890 0.79
SCHEMBL10076693 0.79
SCHEMBL5084320 0.79
SCHEMBL8150730 0.79
SCHEMBL4157344 0.76
SCHEMBL7952337 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4204407-B1 PROCESS GIVAUDAN SA (CH) 2024-06-19 EP claimed
US-20230312506-A1 PROCESS GIVAUDAN SA (CH) 2023-10-05 US claimed
EP-4204407-A1 PROCESS Givaudan SA (CH) 2023-07-05 EP claimed
EP-4204407-B1 PROCESS GIVAUDAN SA (CH) 2024-06-19 EP disclosed
US-20240139087-A1 ORGANIC COMPOUNDS AS TRPM8 ACTIVATORS GIVAUDAN SA (CH) 2024-05-02 US disclosed
US-20240132487-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS GIVAUDAN SA (CH) 2024-04-25 US disclosed
EP-4291553-A1 ORGANIC COMPOUNDS AS TRPM8 ACTIVATORS Givaudan SA (CH) 2023-12-20 EP disclosed
CN-116867775-A Organic compounds as TRPM8 activators 奇华顿股份有限公司 2023-10-10 CN disclosed
US-20230312506-A1 PROCESS GIVAUDAN SA (CH) 2023-10-05 US disclosed
EP-4204407-A1 PROCESS Givaudan SA (CH) 2023-07-05 EP disclosed
CN-116209659-A Method 奇华顿股份有限公司 2023-06-02 CN disclosed
WO-2010014943-A2 METHIONINE ANALOGS AND METHODS OF USING SAME BIOXINESS PHARMACEUTICS, INC. (US) 2010-02-04 WO disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed
US-20090263483-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2009-10-22 US disclosed
WO-2009126938-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCES, LLC (US) 2009-10-15 WO disclosed
WO-2009126401-A1 COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF ABRAXIS BIOSCIENCE, LLC (US) 2009-10-15 WO disclosed
WO-2009126175-A1 COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF ABRAXIS BIOSCIENCE, LLC (US) 2009-10-15 WO disclosed
WO-2009115572-A2 NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF NOVARTIS AG (CH) 2009-09-24 WO disclosed
WO-2009042694-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC. (US) 2009-04-02 WO disclosed
WO-2008155727-A1 PLATINUM (IV) COMPLEXES PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2008-12-24 WO disclosed